Consensus $540.54M. The company said, “TransMedics (TMDX) is raising its full year 2025 revenue guidance to be in the range of $565 million to $585 million, which represents 30% growth at the midpoint compared to the company’s prior year revenue. TransMedics’ full year 2025 revenue guidance as reported on February 27, 2025 was previously in the range of $530 million to $552 million.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group options imply 14.5% move in share price post-earnings
- TransMedics price target raised to $105 from $90 at Piper Sandler
- TransMedics Group’s OCS Drives Structural Transformation in Liver Transplantation with Increased DCD Liver Utilization
- TransMedics Group: Strong Buy Rating Amidst Robust DCD Market Performance and Growth Prospects
- TransMedics Group: Strong Market Position and Growth Potential Justify Buy Rating